Pfizer and Bayer have entered an agreement granting Pfizer worldwide rights to Bayer’s pipeline DGAT-1 inhibitor treatments for obesity and diabetes.
Both companies agreed that Bayer would receive an upfront fee, milestone payments and royalties on sales of any compounds that successfully make it to market. Financial terms of the deal were not disclosed.
The deal is expected to close in the second half of 2006.
The lead compound in the class, BAY 74-4113, is a potential treatment for Type 2 diabetes and obesity currently in Phase I of clinical development.